Ticker Details
SELLAS Life Sciences Group, Inc. SELLAS Life Sciences Group Inc is a biopharmaceutical company. The company is engaged in the development of novel cancer immunotherapies for a broad range of cancer indications. Its pipeline products are Galinpepimut-S and NeuVax.
IPO Date:	April 1, 2008
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$706.67M
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.14 | 3.48%
Avg Daily Range (30 D):	$0.18 | 4.60%
Avg Daily Range (90 D):	$0.13 | 4.72%

Institutional Daily Volume
Avg Daily Volume:	.75M
Avg Daily Volume (30 D):	6.52M
Avg Daily Volume (90 D):	6.96M

Trade Size
Avg Trade Size (Sh.):	369
Avg Trade Size (Sh.) (30 D):	312
Avg Trade Size (Sh.) (90 D):	358

Institutional Trades
Total Institutional Trades:	113
Avg Institutional Trade:	$1.4M
Avg Institutional Trade (30 D):	$1M
Avg Institutional Trade (90 D):	$1.44M
Avg Institutional Trade Volume:	.43M
Avg Institutional Trades (Per Day):	1

Market Closing Trades
Avg Closing Trade:	$1.27M
Avg Closing Trade (30 D):	$.82M
Avg Closing Trade (90 D):	$1.05M
Avg Closing Volume:	454.2K

News

Dec 4, 2025 @ 5:20 PM Blood Cancer Therapeutics Reach Critical Commercia... Source: Prnewswire

Jul 16, 2025 @ 10:51 PM Cancer Pipeline Milestones Coming Fast as Regulato... Source: Prnewswire

Jun 2, 2025 @ 12:00 PM SELLAS Presents Preclinical Efficacy of SLS009 in ... Source: Sellas Life Sciences Group, Inc.

May 12, 2025 @ 5:00 PM Blood Cancer Treatment Market Sees Accelerated Gro... Source: Delveinsight

Feb 27, 2025 @ 3:04 PM Oncology Breakthroughs: How Cancer Research Is Adv... Source: Prnewswire

Financials
	TTM	Q2 2025	Q1 2025
Basic EPS	$-.06	$-.07	$-.07
Diluted EPS	$-.06	$-.07	$-.07
Revenue	$M	$M	$M
Gross Profit
Net Income / Loss	$-6.79M	$-6.6M	$-5.81M
Operating Income / Loss	$-7.08M	$-6.87M	$-6.06M
Cost of Revenue	$M	$M	$M
Net Cash Flow	$M	$M	$M
PE Ratio

Splits
Nov 08, 2019	1:50
Jan 02, 2018	1:30
Nov 14, 2016	1:20